R Mitsuyasu

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Early versus delayed initiation of antiretroviral therapy for Indian HIV-Infected individuals with tuberculosis on antituberculosis treatment
    Sanjeev Sinha
    Department of Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India
    BMC Infect Dis 12:168. 2012
  2. pmc Curing HIV: lessons from cancer therapy
    Ronald Mitsuyasu
    David Geffen School of Medicine at UCLA, UCLA Center for Clinical AIDS Research and Education CARE Center, University of California, Los Angeles, CA 90035, USA
    Curr Opin HIV AIDS 8:224-9. 2013
  3. pmc The antiretroviral efficacy of highly active antiretroviral therapy and plasma nevirapine concentrations in HIV-TB co-infected Indian patients receiving rifampicin based antituberculosis treatment
    Sanjeev Sinha
    Department of Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India
    AIDS Res Ther 8:41. 2011
  4. pmc Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328)
    Ronald J Bosch
    Harvard School of Public Health, Boston MA, USA
    AIDS Res Ther 7:30. 2010
  5. ncbi request reprint Immune therapy: non-highly active antiretroviral therapy management of human immunodeficiency virus-infected patients
    Ronald Mitsuyasu
    University of California, Los Angeles, CARE Center, Los Angeles, California 90095 1793, USA
    J Infect Dis 185:S115-22. 2002
  6. ncbi request reprint The potential role of interleukin-2 in HIV
    R T Mitsuyasu
    UCLA Center for Clinical AIDS Research and Education, University of California, Los Angeles 90095 1793, USA
    AIDS 15:S22-7. 2001
  7. ncbi request reprint Prevention of bacterial infections in patients with advanced HIV infection
    R Mitsuyasu
    Center for Clinical AIDS Research and Education, University of California, Los Angeles 90095 1793, USA
    AIDS 13:S19-23. 1999
  8. pmc Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells
    Ronald T Mitsuyasu
    Center for Clinical AIDS Research and Education, University of California Los Angeles, 9911 West Pico Boulevard, Suite 980, Los Angeles, California 90035, USA
    Nat Med 15:285-92. 2009
  9. ncbi request reprint Open-label phase I study of combination therapy with zidovudine and interferon-beta in patients with AIDS-related Kaposi's sarcoma: AIDS Clinical Trials Group Protocol 057
    S Miles
    Division of Hematology Oncology, UCLA Clinical AIDS Research and Education Center, UCLA School of Medicine, USA
    Cytokines Cell Mol Ther 4:17-23. 1998
  10. ncbi request reprint Update on the pathogenesis and treatment of Kaposi sarcoma
    R T Mitsuyasu
    Division of Hematology Oncology, UCLA School of Medicine, UCLA Center for Clinical AIDS Research and Education, Los Angeles, California 90095 1793, USA
    Curr Opin Oncol 12:174-80. 2000

Collaborators

Detail Information

Publications18

  1. pmc Early versus delayed initiation of antiretroviral therapy for Indian HIV-Infected individuals with tuberculosis on antituberculosis treatment
    Sanjeev Sinha
    Department of Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India
    BMC Infect Dis 12:168. 2012
    ....
  2. pmc Curing HIV: lessons from cancer therapy
    Ronald Mitsuyasu
    David Geffen School of Medicine at UCLA, UCLA Center for Clinical AIDS Research and Education CARE Center, University of California, Los Angeles, CA 90035, USA
    Curr Opin HIV AIDS 8:224-9. 2013
    ..The potential role of cancer chemotherapy and other cancer-directed treatment approaches is discussed in the context of their potential role in helping to eliminate HIV from the infected host...
  3. pmc The antiretroviral efficacy of highly active antiretroviral therapy and plasma nevirapine concentrations in HIV-TB co-infected Indian patients receiving rifampicin based antituberculosis treatment
    Sanjeev Sinha
    Department of Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India
    AIDS Res Ther 8:41. 2011
    ..abstract:..
  4. pmc Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328)
    Ronald J Bosch
    Harvard School of Public Health, Boston MA, USA
    AIDS Res Ther 7:30. 2010
    ..In A5051, 53 patients from A328 who had previously received IL-2 were allowed to continue IL-2 for an additional 80 weeks; 27 patients who had received ART alone received IL-2 for 80 weeks...
  5. ncbi request reprint Immune therapy: non-highly active antiretroviral therapy management of human immunodeficiency virus-infected patients
    Ronald Mitsuyasu
    University of California, Los Angeles, CARE Center, Los Angeles, California 90095 1793, USA
    J Infect Dis 185:S115-22. 2002
    ....
  6. ncbi request reprint The potential role of interleukin-2 in HIV
    R T Mitsuyasu
    UCLA Center for Clinical AIDS Research and Education, University of California, Los Angeles 90095 1793, USA
    AIDS 15:S22-7. 2001
    ..Further evaluation of the clinical efficacy of IL-2 in HIV-infected patients is expected to provide important information on the utility of recombinant human IL-2 in HIV disease...
  7. ncbi request reprint Prevention of bacterial infections in patients with advanced HIV infection
    R Mitsuyasu
    Center for Clinical AIDS Research and Education, University of California, Los Angeles 90095 1793, USA
    AIDS 13:S19-23. 1999
    ..No unexpected or new adverse events were observed and there were no differences in plasma HIV-1 RNA levels between the groups...
  8. pmc Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells
    Ronald T Mitsuyasu
    Center for Clinical AIDS Research and Education, University of California Los Angeles, 9911 West Pico Boulevard, Suite 980, Los Angeles, California 90035, USA
    Nat Med 15:285-92. 2009
    ..This study indicates that cell-delivered gene transfer is safe and biologically active in individuals with HIV and can be developed as a conventional therapeutic product...
  9. ncbi request reprint Open-label phase I study of combination therapy with zidovudine and interferon-beta in patients with AIDS-related Kaposi's sarcoma: AIDS Clinical Trials Group Protocol 057
    S Miles
    Division of Hematology Oncology, UCLA Clinical AIDS Research and Education Center, UCLA School of Medicine, USA
    Cytokines Cell Mol Ther 4:17-23. 1998
    ..Further studies of this agent should be in the context of four-drug antiretroviral regimens where viral suppression is greatest and any antitumor activity of IFN-beta may be observed...
  10. ncbi request reprint Update on the pathogenesis and treatment of Kaposi sarcoma
    R T Mitsuyasu
    Division of Hematology Oncology, UCLA School of Medicine, UCLA Center for Clinical AIDS Research and Education, Los Angeles, California 90095 1793, USA
    Curr Opin Oncol 12:174-80. 2000
    ..In this review, recent advances in our understanding of the pathogenesis of KS are highlighted and a brief overview of current approaches to the treatment of this tumor is provided...
  11. ncbi request reprint Gene therapy for the treatment of AIDS: animal models and human clinical experience
    R G Amado
    Division of Hematology Oncology, UCLA School of Medicine, 11 964 Factor Building, Los Angeles, CA 90095, USA
    Front Biosci 4:D468-75. 1999
    ..Herein, we review recent advances in transduction methods, data from in vivo preclinical studies in relevant animal models, and emerging results derived from pilot clinical gene therapy studies...
  12. ncbi request reprint The effect of zidovudine treatment on serum neopterin and beta 2-microglobulin levels in mildly symptomatic, HIV type 1 seropositive individuals
    H Z Bass
    Center for Interdisciplinary Research in Immunology and Disease, Department of Medicine, University of California, Los Angeles
    J Acquir Immune Defic Syndr 5:215-21. 1992
    ..Subjects with greater reductions of serum neopterin or beta 2M tended to maintain lower levels of these markers with continued zidovudine administration.(ABSTRACT TRUNCATED AT 250 WORDS)..
  13. ncbi request reprint A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024)
    J Michael Kilby
    University of Alabama at Birmingham, Birmingham, AL 35294 2050, USA
    J Infect Dis 194:1672-6. 2006
    ..Significant changes were not detected for HIV-specific lymphoproliferative responses in any arm. This exploratory protocol provides useful clinical data for future therapeutic immunization trial design...
  14. ncbi request reprint The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328
    Ronald Mitsuyasu
    Department of Internal Medicine, University of California Los Angeles, USA
    Arch Intern Med 167:597-605. 2007
    ..Interleukin 2 (IL-2) administration increases CD4 counts in persons with higher counts. This study investigated persons with moderately advanced human immunodeficiency virus infection receiving highly active antiretroviral therapy (HAART)...
  15. ncbi request reprint Interleukin-2 Increases CD4+ lymphocyte numbers but does not enhance responses to immunization: results of A5046s
    Hernan Valdez
    Case Western Reserve University and University Hospitals of Cleveland, Ohio 44106, USA
    J Infect Dis 187:320-5. 2003
    ..Despite dramatic increases in CD4(+) lymphocyte counts, IL-2 did not enhance immunization responses...
  16. ncbi request reprint Anemia in HIV infection: clinical impact and evidence-based management strategies
    Paul A Volberding
    University of California, San Francisco, CA, USA
    Clin Infect Dis 38:1454-63. 2004
    ....
  17. ncbi request reprint Differential effect of interleukin-2 treatment on primary and secondary immunizations in HIV infected individuals
    Haydar Kuekrek
    Department of Pathology, Case Western Reserve University and University Hospitals of Cleveland, Cleveland, Ohio 44116, USA
    AIDS 19:1967-74. 2005
    ..As interleukin (IL)-2 therapy increases CD4 cell counts in HIV infected subjects, it emerged as a candidate for the partial restoration of immune competence in this disease...
  18. ncbi request reprint Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor alpha, and markers of immune activation in HIV-infected subjects receiving interleukin 2
    Beverly E Sha
    Section of Infectious Diseases, Department of Medicine, Rush Medical College, Chicago, Illinois 60612 3833, USA
    AIDS Res Hum Retroviruses 18:661-5. 2002
    ..Pretreatment with etanercept may blunt activation of IL-6 and CRP expression induced by rhIL-2. The safety and utility of etanercept in HIV-infected persons should be explored further...